Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
about
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaTumor immunotherapy across MHC barriers using allogeneic T-cell precursorsAssociation of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)Developing strategies in the immunotherapy of leukemiasAdoptive T-cell therapy for LeukemiaPreferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesQuantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemiaT-cell-based therapies for malignancy and infection in childhood.Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cellsTargeted therapies for the myeloid leukaemias.BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.Adoptive cellular therapy: a therapeutic reality?Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation.Immunotherapy targets in pediatric cancer.Interferon alpha and T-cell responses in chronic myeloid leukemia.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.Adoptive T-cell transfer in cancer immunotherapy.Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.Telomerase immunity from bench to bedside: round one.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Immunotherapeutic approaches in chronic myelogenous leukemia.Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.PR1 vaccination in myeloid malignancies.Dendritic cell-based immunotherapy for myeloid leukemias.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.Regulation of hematopoietic and leukemic stem cells by the immune system.Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia.Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells.
P2860
Q24604091-D9D0560E-D9EC-4A50-8E02-029DE5F838C2Q24647124-8214758A-853E-41A9-A870-7CFDF220E44FQ24797667-FAFEAA1D-9C31-4EFC-B7CB-087101602E1EQ26996310-29783708-DD76-4C7A-8B0E-791C7EB00242Q27006934-EFF5BDE7-13FA-4479-A0A4-C50B156B09C4Q28190215-8C806109-DF6D-40F6-A239-02ADE50069DBQ28212054-EAA9136E-DFFE-4AB5-9778-7C277F3FB292Q33750862-49107379-6F2D-4640-ABBF-3F8B41A99BA7Q33895386-296B1D5C-CD03-44B8-8068-38A3EF2B6FB5Q34024223-7F824ED1-E790-4EFF-85CE-E117CCFD28DCQ34074884-ED27FEC0-7CF8-4F26-9E62-198D63E70B14Q34430354-A712F942-9916-442C-8A49-BA21852350BCQ34875170-26CE9C09-EA8B-41A9-9C22-00ECC7FF406CQ35760924-DCE2AC56-C845-496A-9DA6-DFC30B11A61FQ35809452-CD18291B-3FB5-41BA-8926-DCB202AC2FADQ35971029-5D76FF35-CBB5-4CAC-8C0D-93CCE8E101DBQ35994924-9F925DBA-24C2-4C12-9EF4-1299F288ADB7Q36021163-2BBE8175-1C0E-4BBC-8963-2FFD1114E006Q36194635-0C099D67-2BFF-4ABD-9AFF-8FDD044BEF70Q36316627-D1CC6343-8B7F-4B41-8728-AEEE1397FCDDQ36375927-8D6B55E1-1093-48AE-91FD-B3278BA8F8BCQ36471818-569E4079-28E3-4CBC-869E-7C23D57E3CC1Q36694195-327FD692-1CEF-42C8-9BA2-53C640D5B4B9Q36745749-BBD656BF-19E9-47F5-BCE8-F3397A0808A1Q36793112-BA705143-2DAD-4F5B-9DF4-33101E8CFCFEQ36813562-40E10B63-4EC4-4CD8-987A-E2B84EC72528Q37088532-F521D223-49F3-40EE-9CFE-798F5F7AA50CQ37132861-2F26F8C6-46AF-479C-A773-A319B6F39796Q37132892-29DE8485-6AA3-4EFE-8853-E124E5513D29Q37259568-3FBEF08C-D68B-4D01-963F-3EA414D16789Q37420778-32D0CEDF-6530-4C10-A0BE-9CF90A22EE68Q37428671-921674A7-9430-4AE1-BF08-417CFECA0743Q37445265-85FAEC9E-F5D5-45D0-AEC8-01C859D1EFC3Q37514725-6DC3F728-245C-4D49-B428-E3D3EC70ABF3Q37708939-8695F132-972C-4C3A-BF51-A7F0E8AEEEE9Q37773256-F7961866-EC8D-4568-912C-04EAD2B361C0Q37851050-1439BC46-1892-4A5F-AA67-2EF53FD98E52Q38225994-812B35FE-B58F-4D2B-A59A-DED95CB466A1Q38305687-6099DFF7-3099-4DF9-9D3C-0AF1EF7740E9Q39374243-26CD00A4-FE50-4A9A-B7AD-77822C132AA7
P2860
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@en
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@nl
type
label
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@en
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@nl
prefLabel
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@en
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@nl
P2093
P2860
P921
P356
P1476
Cytotoxic T cell response agai ...... chronic myelogenous leukemia.
@en
P2093
Garcia-Pons F
Langlade-Demoyen P
Lemonnier FA
Vernant JP
P2860
P304
P356
10.1172/JCI488
P407
P577
1998-05-01T00:00:00Z